Sign in
FATE Stock Price, Chart, Stats & News
Fate Therapeutics, Inc.
Save
240.11M
Market cap
–
Current P/E
–
Forward P/E
FATE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -94.12% |
Operating margin | -2222.45% |
Pretax margin | -2051.08% |
Net margin | -2051.08% |
Effective tax rate | – |
ROA | -42.74% |
ROE | -55.02% |
D/E | 0.38x |
Interest coverage ratio | – |
FATE valuation
P/E | – |
P/S | 20.47x |
P/B | 0.67x |
P/CF | -1.31x |
P/FCF | -1.21x |
P/OCF | -1.31x |
PEG | -0.08x |
EV multiple | -0.75x |
About
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs.
Similar securities
Based on sector and market capitalization
Report issue